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LETTERS TO THE EDITOR 
Effect of inhaled nitric oxide on left ventricular and 
pulmonary vascular function 
To the Editor: 
The conclusions of Argenziano and associates l contra-
dicted their evidence. They concluded: "Inhaled nitric oxide 
reduced pulmonary vascular resistance but did not alter 
myocardial contractility or diastolic function." However, 
their Table I showed the following evidence of increased 
left heart failure after their 6 experimental pigs inhaled 
nitric oxide (NO): Cardiac output and ejection fraction 
decreased while left ventricular end-diastolic volume and 
pressure increased. The authors cited 3 reports that left atri-
al pressure increased and pulmonary edema appeared when 
subjects with left ventricular dysfunction inhaled NO ther-
apeutically. This was further evidence that myocardial con-
tractility and diastolic function deteriorated after inhalation 
of NO. 
The authors' second point was that NO lowered the pul-
monary vascular resistance (PVR), which they calculated 
by the standard formula that is derived from Poiseuille's 
equation.2 However, "since the experiments from which the 
equation was derived were performed in straight, rigid tubes 
with steady, streamlined flow of an ideal, viscous fluid, the 
relationship cannot be directly applied to the vascular sys-
tem, in which the vessels are neither straight nor rigid, the 
blood is not a simple viscous fluid, and the flow is not 
always streamlined."2 
The common formula for "vascular resistance" is: 
PVR = PAP - LAP 
Cardiac output 
where PAP is mean pulmonary artery pressure and LAP is 
mean left atrial pressure. 
This can be misleading, because raising the left atrial 
pressure, which Argenziano and colleagues 1 observed in 
their pigs, decreases the numerator and thereby the calcu-
lated PVR. This can happen with no change in pulmonary 
artery pressure. Raising the left atrial pressure obviously 
obstructs pulmonary blood flow, but it decreases the calcu-
lated PVR. A similarly misleading result occurs when this 
formula is applied to systemic vascular resistance while 
phenyleprinei (Neo-Synephrine) is administered: The right 
atrial pressure increases more than the mean arterial pres-
sure increases, thereby decreasing the numerator in the re-
sistance equation. As a result, while vasoconstriction de-
creases the' force of the femoral pulses, the calculated 
systemic vascular resistance becomes abnormally low, the 
opposite of the true state. 
Although the number of pigs was too small to allow ade-
quate statistical evaluation of some measured parameters, the 
authors did show well that during controlled heart failure 
inhaled NO decreased pulmonary artery pressure despite ele-
vated left atrial pressure. 
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Reply to the Editor: 
We appreciate Dr Krohn's interest in our study and the 
opportunity to address his comments regarding our assess-
ment of myocardial function and the limitations associated 
with calculation of pulmonary vascular resistance. We 
respectfully disagree with Dr Krohn's assertion that our con-
clusions contradict our evidence. As mentioned in our article, 
previous reports of pulmonary edema and left atrial pressure 
elevation after administration of inhaled nitric oxide (iNa) in 
patients with myocardial dysfunction raised concerns about 
potential myocardial depressant effects of this agent. Our 
study was undertaken specifically to assess the effects of this 
pulmonary vasodilator on myocardial systolic and diastolic 
function. Because clinical hemodynamic parameters such as 
cardiac output and left ventricular end-diastolic pressure 
(LVEDP) are influenced by a number of factors (including 
preload, afterload, contractility, heart rate, and diastolic com-
pliance) in a complex fashion, these parameters cannot be 
individually used to accurately assess myocardial contractili-
ty or diastolic compliance unless all other factors (ie, preload, 
afterload, and heart rate) are accounted for. Therefore we 
assessed systolic function by 2 well-accepted load-indepen-
dent measures of contractility, the preload-recruitable stroke 
work relationship (PRSWR) and the end-systolic pressure-
volume relationship (ESPVR). We assessed diastolic function 
by the end-diastolic pressure-volume relation (EDPVR). Our 
data demonstrated clearly that despite slight increases in 
LVEDP, contractility and diastolic function as assessed by 
these measures was not altered by administration of iNa. Dr 
Krohn cites statistically insignificant decreases in cardiac out-
put and increases in left ventricular volume from Table I of 
our article as "evidence for deterioration of myocardial con-
tractility and diastolic dysfunction," but he ignores increases 
in mean arterial pressure and systemic vascular resistance and 
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decreases in central venous pressure and heart rate, listed in 
the same table, all of which are consistent with a decrease in 
cardiac output in the absence of reduced contractility. 
With respect to Dr Krohn's comments regarding the limita-
tions associated with the application of the widely used stan-
dard pulmonary vascular resistance (PVR) equation, we are in 
agreement that this method of PVR calculation is imperfect 
for the reasons he has enumerated. However, Dr Krohn seems 
to confuse PVR (affected by pulmonary vascular properties) 
with right ventricular afterload (affected additionally by left 
atrial pressure, LAP). Pulmonary vasodilation may reduce 
PVR while raising LAP, thus leaving PAP and right ventricu-
lar afterload relatively unchanged. 1 This ought not be viewed 
as misleading; rather it is simply a natural consequence of the 
right and left sides of the hearts being connected in series. 
Furthermore, inasmuch as previous clinical and experimental 
work have already well established the pulmonary vasodilato-
ry effects of iNO, this was not the focus of our experiment. 
Rather, since clinically and experimentally observed increas-
es in LAP may be due to a decrease in PVR and/or alterations 
in ventricular function, we sought to establish whether iNO 
affects left ventricular systolic or diastolic properties, as 
described above. We found that the increase in LAP was not 
due to depression of ventricular function, but was simply a 
consequence of pulmonary vasodilation. 
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Deep hypothermic circulatory arrest and retrograde 
cerebral perfusion 
To the Editor: 
I was disturbed when I read the article by Okita and associ-
ates concerning deep hypothermic circulatory arrest (DHCA) 
anf retrograde cerebral perfusion (RCP) in patients undergo-
ing operations on the aortic arch in the January 1998 issue of 
the Journal (1998;115: 129-38). I have several major concerns 
about the paper. The most important concern relates to the fact 
that the authors are describing a relatively new technique of 
cerebral protection, namely RCP, and yet they have failed to 
include among their investigators or authors any neurologists 
or psychologists. There is no statement in the methods section 
of the paper regarding complete neurologic examination of 
their patients and whether this was performed before and after 
the operations. My own experience would suggest that a sim-
ple retrospective chart review relying on observations by sur-
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gical residents is inadequate to detect subtle focal neurologic 
deficits. For example, how many of these patients had careful 
assessment of their visual fields? How many patients had their 
postoperative fine motor skills compared with their preopera-
tive fine motor skills? In fact, even a neurologic examination 
will not detect many of the cognitive deficits that can only be 
identified by careful psychometric testing. In the absence of 
such testing, it is unjustified for the authors to make the state-
ment: "We empirically consider that a DHCA + RCP period 
of up to 80 minutes under a nasopharyngeal temperature of 
18°C is safe." This statement is all the more questionable after 
viewing Fig 1, which demonstrates that patients who under-
went a combined DHCA + RCP time of 70 to 80 minutes had 
an incidence of death or delirium that was greater that 50%. 
The authors state: "Postoperative transient delirium has been 
defined as a transient minor neurologic deficit such as disori-
entation and character change with no neurologic sequelae." 
This statement bears resemblance to the previously often 
heard statement within pediatric cardiac surgery that seizures 
in the early postoperative period in infants are of no long-term 
significance. Our prospective randomized trial of DHCA 1 has 
demonstrated that perioperative seizures do indeed have an 
association with subsequent impairment, as assessed by our 
developmental psychologists using comprehensive testing at 
age 1 year and 4 years with ongoing studies of this same 
cohort at age 8 years. 
Until clinical studies have been undertaken with careful 
preoperative and postoperative neurologic examination by 
neurologists, as well as psychometric testing, I believe that 
surgeons should be cautious in using RCP as a means of 
extending DHCA. If it is possible to extrapolate from the 
pediatric experience with DHCA, periods of DHCA greater 
that 30 to 45 minutes in length at a tympanic membrane tem-
perature of 15°C should be used with great caution. 
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To the Editor: 
We thank Dr Jonas for his informative response regarding 
our article and appreciate his contributions to this field in 
pediatric cardiac surgery. 
We did have neurologists or radiologists involved in this 
study. They did preoperative or postoperative neurologic 
examinations of our patients or reviewed the radiologic 
images. We must apologize for not including their names 
among the authors of our paper and for not stating their con-
